Hypothesis

Age-associated immune senescence reprograms colonic mucin O‑glycosylation, decreasing specific glycan epitopes (e.g., core‑3 sialylated structures) that Akkermansia muciniphila requires for optimal binding and growth. This glycan shift occurs independently of overall mucus thickness and precedes the observed drop in A. muciniphila abundance, making immune‑mediated mucin remodeling—not merely mucus erosion—the upstream driver of gut dysbiosis in aging.

Mechanistic Reasoning

1. IL‑22/TLR2 signaling controls glycosyltransferase expression – IL‑22 induces STAT3‑dependent up‑regulation of C3GnT (core‑3 β1,6‑N‑acetylglucosaminyltransferase) and ST3GAL4 (α2,3‑sialyltransferase) in goblet cells, generating the mucin epitopes that A. muciniphila’s mucin‑binding adhesin Amuc_1100 recognizes. TLR2 signaling further sustains GCNT3 activity via MyD88‑NF‑κB. In aging, reduced IL‑22 (AhR decline) and TLR2 downregulation lower these enzymes, producing mucins deficient in core‑3 sialylated glycans.
2. Glycan loss directly limits A. muciniphila colonization – In vitro, A. muciniphila growth on mucin substrates is rescued by adding purified core‑3 sialylated oligosaccharides but not by generic mucin polysaccharides. Thus, the bacterium’s niche depends on specific glycan motifs rather than bulk mucus volume.
3. Feedback loop with mucosal immunity – A. muciniphila‑derived propionate promotes Treg differentiation and IL‑10 production. When glycan‑dependent colonization falls, propionate drops, weakening Treg‑mediated restraint of inflammaging, which further suppresses IL‑22/TLR2 signaling—a self‑amplifying circuit.

Testable Predictions

• Prediction 1: Colonic mucus from aged mice (or humans) will show a specific reduction in core‑3 sialylated O‑glycans, detectable by LC‑MS/MS glycomics, while total mucin protein (e.g., MUC2) remains unchanged or only modestly decreased.
• Prediction 2: Supplementing aged mice with exogenous core‑3 sialylated oligosaccharides (or goblet‑cell‑targeted over‑expression of C3GnT/ST3GAL4) will restore A. muciniphila colonization to youthful levels without altering overall mucus thickness.
• Prediction 3: Germ‑free mice colonized with an A. muciniphila mutant lacking the Amuc_1100 adhesin will fail to rescue the age‑related glycan defect, confirming that bacterial sensing of the glycan epitope is required for the mutualistic loop.

Experimental Approach

1. Glycomic profiling – Isolate colonic mucus from young (3 mo) and aged (24 mo) mice; perform hydrophilic interaction LC‑MS/MS to quantify core‑3 sialylated versus core‑1/neutral glycans.
2. Intervention – Treat aged mice with daily oral gavage of purified core‑3 sialylated trisaccharide (2 g/kg) for 4 weeks; measure A. muciniphila qPCR, mucus thickness (confocal microscopy), and inflammatory cytokines (IL‑6, TNF‑α).
3. Genetic validation – Use Villin‑CreERT2; C3GnT^fl/fl mice to inducibly delete the glycosyltransferase in goblet cells of young animals; assess whether this phenocopies the aged mucin glycan loss and A. muciniphila decline.

Falsifiability

If aged mucus shows no significant loss of core‑3 sialylated glycans, or if restoring those glycans fails to improve A. muciniphila abundance, the hypothesis would be refuted. Conversely, confirmation would position immune‑driven glycosylation as a mechanistic linchpin linking inflammaging to microbial loss, offering a precise target (glycan restoration) to break the aging‑immune‑microbiota cycle.